RADIOSYNTHESIS AND CHIRAL SEPARATION OF C-11 LABELED BORONOPHENYLALANINE FOR BNCT STUDIES WITH PET.
The overall goal of this research is to combine two powerful methodologies, boron neutron capture therapy (BNCT) and positron emission tomography (PET), to advance the treatment of patients with malignant brain tumors. BNCT is a method to selectively deliver lethal alpha radiation to a tumor through the administration of a boron-10 containing drug, and irradiation of the tumor area with neutrons [1]. L-Boronophenylalanine (L-{sup 10}BPA) is a boron-10 containing amino acid currently used for BNCT [4]. In order to perform neutron dosimetry, it is essential to determine tumor boron-10 levels in the course of the therapy. PET has the ability to measure the concentration of drugs labeled with positron-emitting isotopes in the human body [2]. 2-Fluoro-4-borono-phenylalanine ([{sup 18}F]FBPA) has been labeled as a surrogate marker for L-BPA for pharmacokinetic studies in brain tumor patients [3]. However, [{sup 18}F]FBPA is a different drug than L-BPA because it contains a fluorine atom. We report here the labeling of L-BPA with C-11, which has the advantage of being chemically identical to L-BPA. Carbon-11 is also well suited to repeated studies within the same PET scanning session.
- Research Organization:
- Brookhaven National Lab. (BNL), Upton, NY (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research (ER) (US)
- DOE Contract Number:
- AC02-98CH10886
- OSTI ID:
- 781788
- Report Number(s):
- BNL-68115; KP140102; R&D Project: CO11; KP140102; TRN: US0102963
- Resource Relation:
- Conference: INTERNATIONAL SYMPOSIUM RADIOPHARMACEUTICAL CHEMISTRY, INTERLAKEN (CH), 06/10/2001--06/15/2001; Other Information: PBD: 10 Jun 2001
- Country of Publication:
- United States
- Language:
- English
Similar Records
An update on the clinical trial of BNCT at the BMRR
Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent